| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Zhengye Biotechnology Holding Limited$1.23
0 (0%)
Market Cap
44.29 M
EPS
-0.21
P/E Ratio
-
Value Trade
4.60 K
-6.56 %
Week
-11.33 %
1 Month
0.17 %
3 Month
-58.02 %
6 Month
-76.95 %
5 Year
-76.95 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
183.24 K
52 Week Range
0.68 - 13.08
% held by Insiders
74.06 %
% held by Institutions
0.41 %
Enterprise Value
55.74 M
Total Shares
10.97 M
Short %
0.74 %
Float Shares
9.19 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZYBT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZYBT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZYBT▼ -64.4%on this news· ran to -83% by day 1
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
Zhengye Biotechnology Holding Limited has addressed unusual trading activity in its Class A ordinary shares, stating it is not aware of any material non-public information that would explain the increase. The company reassures that its operations are ongoing as usual and has been in contact with Nasdaq regarding the situation. Shareholders are advised to rely on official filings for information.
Read more →ZYBTZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Zhengye Biotechnology Holding Limited received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company has until November 25, 2026, to meet the requirement by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Despite this, the company's operations remain unaffected, and it is considering options to regain compliance.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
Zhengye Biotechnology Holding Limited reported its financial results for FY 2025, showing a significant decline in net revenue and gross profit compared to FY 2024. Despite challenges in the swine vaccine market and a net loss of RMB83.0 million, the company noted growth in its other vaccine segments and achieved several regulatory milestones. The company remains focused on long-term growth strategies and international market expansion.
Read more →ZYBTZhengye Biotechnology Holding Limited Notice of 2026 Annual General Meeting of Shareholders To Be Held on March 24, 2026 at 8:00 a.m. ET NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “M
Zhengye Biotechnology Holding Limited has announced its 2026 Annual General Meeting (AGM) scheduled for March 24, 2026, at 8:00 a.m. ET. The meeting will take place at the Jilin Economic & Technical Development Zone in China, with options for virtual participation via webcast. Shareholders eligible to vote must be on record by February 12, 2026, and the board recommends approval of several key proposals, including the election of directors and share reclassification.
Read more →ZYBTZhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders
Zhengye Biotechnology Holding Limited's Chairman, Mr. Zhenfa Han, shared a letter to shareholders detailing the company's achievements in 2025 and outlining strategic priorities for 2026. The company focuses on enhancing its R&D, expanding its product portfolio, and improving customer engagement. Zhengye aims to capitalize on the recovery of China's swine market while also venturing into the companion animal sector.
Read more →ZYBTZHENGYE BIOTECHNOLOGY HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of RMB and US$, except for number of shares) As of
Zhengye Biotechnology Holding Limited reported its unaudited condensed consolidated financial statements, revealing significant losses. For the six months ending June 30, 2025, the company experienced a net loss of 25,550 RMB, which marks a deterioration compared to the previous period. Operating income also declined sharply, and comprehensive income reflects ongoing operational challenges and financial instability. The assets and liabilities indicate a complex financial situation, necessitating strategic reconsideration for the future.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research,...
Zhengye Biotechnology Holding Limited reported its fiscal year 2024 financial results, revealing a 12% decrease in net revenues to RMB 186.4 million. The company is strategically diversifying its customer base by reducing swine vaccine sales to mitigate risks. Despite challenges, Zhengye continues to invest in R&D and has made strides in the pet vaccine market, receiving two important veterinary drug certifications.
Read more →ZYBT▼ -12.3%on this news
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F Jilin, China
Zhengye Biotechnology Holding Limited has received a Delinquency Letter from NASDAQ due to its late filing of the annual Form 20-F for the fiscal year ending December 31, 2024. The notice states that the company is not in compliance with NASDAQ Listing Rule 5250(c)(1). Zhengye has 60 days to submit a Compliance Plan to regain compliance and may receive a 180-day extension if the plan is accepted. Despite the notice, the letter does not have an immediate adverse impact on the listing of the company's shares.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option Jilin, China
Zhengye Biotechnology Holding Limited announced the full exercise of the underwriters' over-allotment option related to its recent initial public offering. This decision led to the purchase of an additional 225,000 ordinary shares at $4.00 each, increasing the total gross proceeds to $6.9 million. The funds will be allocated towards acquiring vaccine production companies and conducting research and development projects. The company's products, with a focus on veterinary vaccines for livestock, are already present in various regions across China and export markets.
Read more →ZYBTZhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering Jilin, China
Zhengye Biotechnology Holding Limited has announced the pricing of its initial public offering (IPO) of 1,500,000 ordinary shares at $4.00 per share. The shares have been approved for trading on the Nasdaq Capital Market under the ticker symbol 'ZYBT' and are expected to begin trading on January 7, 2025. The company anticipates gross proceeds of $6 million from the offering, which will be utilized for acquisitions and research and development in veterinary vaccines. The offering is set to close around January 8, 2025, pending regulatory approvals.
Read more →Competitive Position
How ZYBT ranks across every disease it competes inCompetitive Position is a premium feature
See how ZYBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial